Comparative Pharmacology
Head-to-head clinical analysis: BREO ELLIPTA versus HYDROCORTISONE VALERATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BREO ELLIPTA versus HYDROCORTISONE VALERATE.
BREO ELLIPTA vs HYDROCORTISONE VALERATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of fluticasone furoate, a corticosteroid that binds to glucocorticoid receptors to inhibit inflammatory gene transcription, and vilanterol, a long-acting beta2-adrenergic agonist that activates adenylate cyclase leading to bronchodilation.
Corticosteroid that binds to glucocorticoid receptors, modulating gene expression to induce anti-inflammatory, antipruritic, and vasoconstrictive effects.
One inhalation (100 mcg fluticasone furoate / 25 mcg vilanterol) once daily via oral inhalation.
Apply a thin film to affected area twice daily. Topical use only.
None Documented
None Documented
Fluticasone furoate: 24 hours (supports once-daily dosing). Vilanterol: 11 hours (supports once-daily dosing).
Terminal elimination half-life is approximately 2-3 hours for the parent drug; 18-36 hours for the active metabolites (clinical context: duration of action is prolonged due to local tissue retention and metabolite activity)
Fluticasone furoate is eliminated primarily via fecal excretion (approximately 101% of an oral dose) due to biliary clearance, with minimal renal excretion (<1%). Vilanterol is eliminated via metabolism and subsequent renal (approximately 70% of an IV dose) and fecal (approximately 30% of an IV dose) excretion.
Renal (approximately 80% as metabolites, <1% unchanged), fecal/biliary (approximately 20% as metabolites)
Category C
Category D/X
Corticosteroid/Beta-2 Agonist Combination
Corticosteroid